The authors reported a relative risk reduction for dementia with HRs for GLP-1 RAs of 0.47 (95% CI 0.25 to 0.86) and 0.89 (95% CI 0.86 to 0.93) relative to other diabetes treatments and placebo in the trials and cohort data, respectively. The gene discussed is GLP1R; the disease is dementia.